Status:
COMPLETED
Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock
Lead Sponsor:
Vantive Health LLC
Collaborating Sponsors:
Gambro Lundia AB
Baxter Healthcare Corporation
Conditions:
Sepsis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Septic shock is a major cause of mortality and morbidity in critically ill patients. Septic Shock is associated with an overwhelming, systemic overflow of pro inflammatory and anti-inflammatory mediat...
Eligibility Criteria
Inclusion
- Patient with a septic shock diagnosed by the medical staff team.
- Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (≥ 1.0 mg/h of norepinephrine or epinephrine) for ≥ 120 minutes and \< 24h.
Exclusion
- Age (years) \< 18 or \> 85.
- Weight \>120 kg
- Thrombocytopenia 50\< G/l or Neutrophils \<0.5 Giga/l
- Contra indication to heparin anticoagulation.
- Patient requiring catecholamines (epinephrine ≥ 1 mg/h or norepinephrine ≥ 1 mg/h) for \>24h.
- Patient admitted to the ICU ≥ 7 days before the inclusion criteria.
- Comorbid conditions with an expected survival \< 6 months
- Inclusion (\<28 days) in another study interfering with the goals of the current investigation.
- Pregnancy
- Immune compromised patients (e.g. being treated for cancer, treated by immunosuppressors or steroids, AIDS).
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00922870
Start Date
April 1 2009
End Date
March 1 2013
Last Update
March 13 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU hospital
Clermont-Ferrand, France, 63003
2
Hopital Le Bocage
Dijon, France, 21079
3
Centre Hospitalier Marc JACQUET
Melun, France, 77 000
4
Hopital Tenon
Paris, France, 75020